<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04640571</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00090086</org_study_id>
    <nct_id>NCT04640571</nct_id>
  </id_info>
  <brief_title>Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition</brief_title>
  <official_title>Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study employs two-sub-studies that share a common placebo arm.&#xD;
&#xD;
      The objective of one sub-study is to assess the impact of metformin on pravastatin and&#xD;
      chenodeoxycholic acid pharmacokinetics. We hypothesize that metformin represses the bile salt&#xD;
      export pump (BSEP) in the liver, which excretes pravastatin and chenodeoxycholic acid from&#xD;
      the liver into the bile.&#xD;
&#xD;
      The objective of the other sub-study is to assess the impact of polysorbate 80 on&#xD;
      valacyclovir, chenodeoxycholic acid, and enalaprilat pharmacokinetics. We hypothesize that&#xD;
      polysorbate 80 inhibits uptake transporters in the intestine, which absorb valacyclovir and&#xD;
      chenodeoxycholic acid in the gut via the peptide transporter 1 (PepT1) and apical sodium-bile&#xD;
      acid transporter (ASBT), respectively. Enalaprilat is passively absorbed but with low&#xD;
      permeability, and thus serves as a passive absorption reference.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Actual">November 1, 2021</completion_date>
  <primary_completion_date type="Actual">November 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area-Under-the-Curve (AUC) of pravastatin</measure>
    <time_frame>0-10 hours</time_frame>
    <description>pravastatin exposure after metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of pravastatin</measure>
    <time_frame>0-10 hours</time_frame>
    <description>pravastatin Cmax after metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area-Under-the-Curve (AUC) of chenodeoxycholic acid after metformin</measure>
    <time_frame>0-10 hours</time_frame>
    <description>chenodeoxycholic acid exposure after metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of chenodeoxycholic acid after metformin</measure>
    <time_frame>0-10 hours</time_frame>
    <description>chenodeoxycholic acid Cmax after metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area-Under-the-Curve (AUC) of acyclovir</measure>
    <time_frame>0-10 hours</time_frame>
    <description>acyclovir exposure after polysorbate 80</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of acyclovir</measure>
    <time_frame>0-10 hours</time_frame>
    <description>acyclovir Cmax after polysorbate 80</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area-Under-the-Curve (AUC) of chenodeoxycholic acid after polysorbate 80</measure>
    <time_frame>0-10 hours</time_frame>
    <description>chenodeoxycholic acid exposure after polysorbate 80</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of chenodeoxycholic acid after polysorbate 80</measure>
    <time_frame>0-10 hours</time_frame>
    <description>chenodeoxycholic acid Cmax after polysorbate 80</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area-Under-the-Curve (AUC) of enalapril</measure>
    <time_frame>0-10 hours</time_frame>
    <description>enalapril exposure after polysorbate 80</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of enalapril</measure>
    <time_frame>0-10 hours</time_frame>
    <description>enalapril Cmax after polysorbate 80</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Bile Salt Export Pump (BSEP) Transporter</condition>
  <condition>Polysorbate 80</condition>
  <arm_group>
    <arm_group_label>placebo, then metformin, then polysorbate 80</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metformin, then polysorbate 80, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>polysorbate 80, then placebo, then metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>polysorbate 80, then metformin, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, then polysorbate 80, then metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metformin, then placebo, then polysorbate 80</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pravastatin and chenodeoxycholic acid, after metformin and placebo</intervention_name>
    <description>single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg</description>
    <arm_group_label>metformin, then placebo, then polysorbate 80</arm_group_label>
    <arm_group_label>metformin, then polysorbate 80, then placebo</arm_group_label>
    <arm_group_label>placebo, then metformin, then polysorbate 80</arm_group_label>
    <arm_group_label>placebo, then polysorbate 80, then metformin</arm_group_label>
    <arm_group_label>polysorbate 80, then metformin, then placebo</arm_group_label>
    <arm_group_label>polysorbate 80, then placebo, then metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo</intervention_name>
    <description>single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg</description>
    <arm_group_label>metformin, then placebo, then polysorbate 80</arm_group_label>
    <arm_group_label>metformin, then polysorbate 80, then placebo</arm_group_label>
    <arm_group_label>placebo, then metformin, then polysorbate 80</arm_group_label>
    <arm_group_label>placebo, then polysorbate 80, then metformin</arm_group_label>
    <arm_group_label>polysorbate 80, then metformin, then placebo</arm_group_label>
    <arm_group_label>polysorbate 80, then placebo, then metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is healthy, as determined by screening evaluation that is not greater than 60&#xD;
             days before the first study visit.&#xD;
&#xD;
          -  Subject is male or female between 18 and 65 years of age, inclusive.&#xD;
&#xD;
          -  Subject is an acceptable candidate for venipuncture.&#xD;
&#xD;
          -  Subject is willing to stop all non-routine OTC medications, as well as vitamins,&#xD;
             dietary supplements, and herbals, for 24 hours prior to study drug administration and&#xD;
             during pharmacokinetic study visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a significant medical disease (including cardiovascular, pulmonary,&#xD;
             hematologic, endocrine, immunologic, neurologic, renal, gastrointestinal, metabolic,&#xD;
             or psychiatric).&#xD;
&#xD;
          -  Subject has a clinically significant history or presence of any clinically significant&#xD;
             gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases),&#xD;
             unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney&#xD;
             disease, or other conditions known to interfere with the absorption, distribution,&#xD;
             metabolism or excretion of study drugs.&#xD;
&#xD;
          -  Subject has a history of liver or gallbladder disease, or history of myopathy&#xD;
&#xD;
          -  Subject has a history of angioedema either with or without previous treatment with an&#xD;
             angiotensin converting enzyme inhibitor.&#xD;
&#xD;
          -  Subject was previously diagnosed with diabetes, or treated with antidiabetic agents&#xD;
&#xD;
          -  Subject has a history of alcohol or drug abuse, which in the opinion of the PI or&#xD;
             medical physician, could jeopardize the subject's health or would compromise the&#xD;
             subject's ability to participate in this trial.&#xD;
&#xD;
          -  Subject is pregnant, breast feeding, or trying to become pregnant.&#xD;
&#xD;
          -  Female subject of childbearing potential is unwilling or unable to use a medically&#xD;
             acceptable method of contraception throughout the entire study period and for one week&#xD;
             after the study is completed. Medically acceptable methods of contraception that may&#xD;
             be used by the subject and/or her partner are: oral birth control pill, condom with&#xD;
             spermicide, diaphragm with spermicide, IUD, vaginal spermicidal suppository, surgical&#xD;
             sterilization of patient or their partner(s), abstinence, or hormonal-based patches,&#xD;
             ring, injections, and implants.&#xD;
&#xD;
          -  Subject routinely uses (i.e. daily or weekly) prescription medication except hormonal&#xD;
             birth control medication, routinely uses (i.e. daily or weekly) OTC medication, or&#xD;
             routinely uses niacin to treat hypercholesterolemia. OTC medications do not include&#xD;
             vitamins, dietary supplements, or herbals.&#xD;
&#xD;
          -  Subject routinely uses (i.e. daily or weekly) acid blockers, antacids, anti-diarrhea,&#xD;
             stimulants, appetite suppressants, or anti-nausea medication or other drugs that&#xD;
             modulate GI function.&#xD;
&#xD;
          -  Subject is currently taking metformin, valacyclovir, acyclovir, chenodiol,&#xD;
             pravastatin, enalapril, enalaprilat, or medications known to interact with any of&#xD;
             these medications.&#xD;
&#xD;
          -  Subject has a history or allergy or sensitivity to metformin, valacyclovir, acyclovir,&#xD;
             chenodiol, pravastatin, polysorbate 80, enalapril, enalaprilat, or history of any drug&#xD;
             hypersensitivity or intolerance which, in the opinion of the PI or medical physician,&#xD;
             would compromise the safety of the subject or the study.&#xD;
&#xD;
          -  Subject has liver impairment as assessed by alanine aminotransferase (ALT), aspartate&#xD;
             aminotransferase (AST), or total bilirubin levels greater than the upper limit of&#xD;
             normal (ULN).&#xD;
&#xD;
          -  Subject has renal impairment as assessed by creatinine clearance lower than&#xD;
             60mL/min/1.73m2, using the CKDEPI formula.&#xD;
&#xD;
          -  Subject is not willing or able to be adherent to study protocol (e.g., study visits).&#xD;
&#xD;
          -  Subject has a condition in which in the opinion of the PI or medical physician would&#xD;
             increase risk to the subject or interfere with the integrity of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>James E Polli</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>healthy volunteer</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>excipient</keyword>
  <keyword>transporter</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Chenodeoxycholic Acid</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

